
Opinion|Videos|January 2, 2025
Utilizing Safety Data When Prescribing Ruxolitinib Cream for Atopic Dermatitis
Author(s)Omar Noor, MD, FAAD
The panelist discusses how safety data from clinical trials and real-world evidence should guide physicians in prescribing ruxolitinib cream, including patient monitoring protocols and managing potential adverse effects in atopic dermatitis treatment.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
New Review Confirms How Nonmedicated Skin Care Vehicles Drive Clinical Improvement
2
Zasocitinib Shows High Skin Clearance at Hard-to-Treat Psoriasis Sites
3
Dermatology Times Spot Test: July 19, 2026
4
Soficitinib (ICP-332) Meets Primary Endpoint in Phase 3 Trial for Moderate to Severe AD
5
















